by James Rudge, PhD, Technical Director, Neoteryx | 3 min read
An article published by Nick Verougstraete and Christophe P. Stove in the January 2022 issue of the Journal of Pharmaceutical and Biomedical Analysis, demonstrated a robust analytical validation of eight …
Read Storyby James Rudge, PhD, Technical Director, Neoteryx | 6 min read
An article published in the March 2018 issue of the Journal of Diabetes Science and Technology, reported on the use of blood microsamples to measure C-peptide as a biomarker for …
Read StoryLearn about insights, research, case studies, and tutorials on integrating remote specimen collection, microsampling, and more!
© Neoteryx 2021 | Privacy Policy | Sitemap
421 Amapola Ave
Torrance, CA 90501
This site is protected by reCAPTCHA and the Google Privacy
Policy and Terms of Service apply.
Mitra® devices are intended as a specimen collector and for the storage and transport of biological fluids. They are CE-IVD self-certified in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada, Thailand, and Ukraine. In the United States, Mitra devices are for Research Use Only (RUO). In some countries, Mitra devices may be used in clinical diagnostic laboratory systems after the laboratory has validated their complete system in compliance with relevant rules and regulations. Mitra is a registered trademark of Neoteryx, LLC.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use. hemaPEN® is a registered trademark owned by Trajan Scientific Australia Pty Ltd.
Copyright © 2022 Neoteryx, LLC, Part of the Trajan Family. All rights reserved.